AI a Natural Fit For Cardiovascular Diagnostics

Bardy Diagnostics is developing an artificial intelligence-enabled (AI) screening technology to detect atrial fibrillation (Afib) events. The company presented a poster with data validating the AI strategy at the 39th annual Heart Rhythm Society (HRS). Data from the poster showed the Seattle-based company’s detection technology's validated sensitivity was 95% and the specificity was 91% for an Afib event spanning 10 minutes or longer. Rodney Boleyn is the lead author of the poster research presented at HRS. Boleyn is also a senior software engineer at Bardy. “It’s always been a question of what part of the population has Afib,” Boleyn told MD+DI. “Our interest was to develop an automatic detection mechanism that would be highly viable for finding Afib in a population.” Bardy Diagnostics has already developed the Carnation Ambulatory Monitor (CAM), a P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device. The technology has been cleared by FDA and CE-marked. The next strategy is to get the AI solution FDA-approved and incorporated into the CAM technology. “What we’d love to do is to be able to incorporate this AI-solution into our P-Wave technology, to not only have superior hardware and software, but to be able to apply these automated approaches to then be able to more accurately and more definitively diagnose any type of arrhythmia’s beyond just Afib,” Jonathan Wu, director of Marketing for Bardy, told MD+DI. Gust Bardy, the firm...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news